Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
3:59pm EST
Change (% chg)

$0.07 (+8.56%)
Prev Close
$0.82
Open
$0.82
Day's High
$0.91
Day's Low
$0.81
Volume
153,933
Avg. Vol
45,537
52-wk High
$4.79
52-wk Low
$0.64

Latest Key Developments (Source: Significant Developments)

Sonoma Pharmaceuticals - On Jan 4, Got Letter From Nasdaq Staff Notifying Failure To Maintain Minimum Bid Price Of $1/Shr For Common Stock
Tuesday, 8 Jan 2019 05:14pm EST 

Jan 8 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS - ON JAN 4, GOT LETTER FROM NASDAQ STAFF NOTIFYING FAILURE TO MAINTAIN MINIMUM BID PRICE OF $1/SHARE FOR COMMON STOCK.  Full Article

Sonoma Pharmaceuticals Inc QTRLY Loss Per Share $0.44
Thursday, 8 Nov 2018 04:03pm EST 

Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS RECORD REVENUE IN SECOND QUARTER FY 2019.Q2 REVENUE ROSE 13 PERCENT TO $4.9 MILLION.QTRLY LOSS PER SHARE $0.44.  Full Article

Montreux Equity Partners V, L.P. Reports 8.8 Pct Stake In Sonoma Pharmaceuticals Inc As Of Nov 2
Monday, 5 Nov 2018 04:32pm EST 

Nov 5 (Reuters) - Sonoma Pharmaceuticals Inc ::MONTREUX EQUITY PARTNERS V, L.P. REPORTS 8.8% STAKE IN SONOMA PHARMACEUTICALS INC AS OF NOVEMBER 2, 2018 - SEC FILING.MONTREUX EQUITY PARTNERS V NOW HAVE INTENT TO INFLUENCE POLICIES OF SONOMA PHARMACEUTICALS INC.MONTREUX EQUITY PARTNERS V - ON NOVEMBER 2, 2018, DANIEL TURNER ON BEHALF OF MEP V, SENT LETTER TO BOARD OF SONOMA PHARMACEUTICALS.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SHARON BARBARI, JAY BIRNBAUM & JERRY MCLAUGHLIN SHOULD IMMEDIATELY RESIGN AS BOARD MEMBERS.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY REDUCE BOARD COMPENSATION.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD PURSUE APPROPRIATE STRATEGIC ALTERNATIVES, INCLUDING SALE.MONTREUX EQUITY PARTNERS V - PROPOSED SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY ELIMINATE TAKEOVER DEFENSES, INCLUDING POISON PILL RIGHTS PLAN.  Full Article

Sonoma Pharma Inc Files For Offering Of Up To $6.0 Mln Of Common Stock
Friday, 12 Oct 2018 05:17pm EDT 

Oct 12 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $6.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

Sonoma Pharmaceuticals Announces Results From Study Of HOCL
Tuesday, 28 Aug 2018 07:05am EDT 

Aug 28 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES RESULTS FROM STUDY OF SONOMA’S PERFORMANCE-STABILIZED HOCL™ (HYPOCHLOROUS ACID) IN MANAGEMENT OF ACNE VULGARIS.SONOMA PHARMACEUTICALS -PERFORMANCE-STABILIZED HOCL AS PART OF ACNE MANAGEMENT REGIMEN WILL BECOME AVAILABLE IN U.S. IN WINTER OF 2018.SONOMA PHARMACEUTICALS - NEW HOCL PRODUCTS SHOW "SIGNIFICANT" EFFICACY IN TREATMENT OF MILD-TO-MODERATE ACNE.SONOMA PHARMACEUTICALS INC - BOTH GEL AND SOLUTION OF HOCI WERE EXTREMELY WELL TOLERATED.SONOMA PHARMACEUTICALS - PLANS TO INVESTIGATE EFFICACY OF HOCL ON MODERATE TO SEVERE ACNE VULGARIS.  Full Article

Sonoma Pharmaceuticals Closes $5 Million Public Offering
Tuesday, 6 Mar 2018 07:26pm EST 

March 6 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS INC - ‍ANNOUNCED CLOSING OF PUBLIC OFFERING OF 1,428,570 SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $3.50 PER SHARE.  Full Article

Sonoma Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Of Common Stock
Friday, 2 Mar 2018 08:00am EST 

March 2 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK.SONOMA PHARMACEUTICALS - PRICING OF "BEST EFFORTS" PUBLIC OFFERING OF UP TO 1.4 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.50/SHARE.  Full Article

Sonoma Pharma Revenue $4.8 Million For Third Quarter
Wednesday, 7 Feb 2018 04:05pm EST 

Feb 7 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%.Q3 REVENUE $4.8 MILLION.QTRLY LOSS EARNINGS PER SHARE FROM CONTINUING OPERATIONS $0.73.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 07:05am EST 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article